Pharmaceutical Investing Corvus Presents Updated Biomarker and Clinical Results from Lead Pipeline Programs
Corvus Announces Presentation of Preclinical Data on CPI-818, a First-in-class Covalent Inhibitor of ITK Targeting T-Cell Lymphomas
Pharmaceutical Investing Corvus Pharmaceuticals Announces Initiation of Phase 1/1b Clinical Trial of Investigational Anti-CD73 Antibody, CPI-006
Pharmaceutical Investing Corvus Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
Corvus Pharmaceuticals to Present Data on Lead Oral Checkpoint Inhibitor CPI-444 at Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
Noble Mineral highlights Successful Exploration Results announced by Canada Nickel, including Highest Grade to Date at Mann West
CHARBONE Hydrogen and ABB Sign Agreement to Advance North American Green Hydrogen Production Facilities
